Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 2 study of intravitreal adalimumab for ranibizumab-nonresponder neovascular age-related macular degeneration
2009-017429-21Phase 2Completed
- Sponsor
- Vall d'Hebron University Hospital
- Start
- Dec 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adalimumab in exudative macular degeneration, sponsored by Vall d'Hebron University Hospital. Primary endpoints: Safety of intravitreal adalimumab and Efficacy between baseline and week 24. Started Dec 2009; status: completed.
02
Drugs
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2009-017429-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017429-21.